



2026/27 Seasonal Influenza Vaccination School Outreach Programme
The Supply of Inactivated Influenza Vaccines for Vaccination Activity

Dear Parents,

Our school has joined the Department of Health's 'Seasonal Influenza Vaccination School Outreach Programme 2026/27' The Gold Coast Medical Team, commissioned by the Department of Health, will be visiting our school on 13 November 2026 (Friday), to provide Vaxigrip (HK-68672) (Trivalent inactivated influenza vaccine -Sanofi) for students with parental consent.

The relevant information is attached for your reference. For general queries regarding the vaccination scheme, please contact the Programme Management and Vaccination Division at 21252125 during office hours (Monday to Friday, 9 a.m. - 5:30 p.m.; closed on Saturdays, Sundays, and public holidays).

Please sign the electronic notice on or before 23 October 2026. Should you have any enquiries, please contact Ms. Wong Yee Man at 24712622.


Yours faithfully,

Mr. Tsoi Kwok Wing
(Acting Principal)



Vaccine Information Sheet

Enquiry
Programme Management and Vaccination Division
Tel: 2125 2125
Fax: 2713 9576
E-mail: vacs@dh.gov.hk
Office Hours: Monday to Friday 09:00-17:30 hours. No service on Saturday, Sunday and Public Holiday.



	TetrAflu (Quadrivalent inactivated influenza vaccine - <i>Sinovac</i>)	Vaxigrip (Trivalent inactivated influenza vaccine - <i>Sanofi</i>)	FluMist (Trivalent Live Attenuated Vaccine – <i>AstraZeneca</i>)
Age & Dosage	Adults and children aged over 3 years are administered one 0.5mL dose	Children from 6 months to 17 years of age: one dose of 0.5 mL Adults: one dose of 0.5 mL	For use in persons 2 through 49 years of age.
Mode of Administration	Intramuscular injection in the deltoid	- The preferred route of administration for this vaccine is intramuscular. - Those with bleeding disorders or on anticoagulants should consult their doctors for advice, and consider subcutaneous administration.	FluMist is a nasal spray.
Person who should not receive	- People who are allergic to egg or any component of the vaccine, including excipients, formaldehyde, Triton X-100 and gentamicin. - People who suffer acute diseases, serious chronic disease¹, acute paroxysm of any chronic disease, cold and fever. - People who have un-controlled epilepsy or other progressive nervous system disease, and guillain-barre syndrome. - Those with bleeding disorders or on anticoagulants	- Hypersensitivity to the active substances, to any of the excipients or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9. - Individual suffers from fever on the day of vaccination, vaccination should be deferred till recovery.	- History of severe allergic reaction to any vaccine component or after previous dose of any influenza vaccine; - Concomitant aspirin or salicylate-containing therapy in children and adolescents; - Children 2 years through 4 years who have asthma or who have had a history of wheezing in the past 12 months; - Children and adults who are immunocompromised due to any cause; - Close contacts and caregivers of severely immunosuppressed persons who require a protected environment; - Pregnancy; and - Receipt of influenza antiviral medication within previous 48 hours. - Individual suffers from fever on the day of vaccination, vaccination should be deferred till recovery.
Pregnancy and Breastfeeding	No clinical trial data on the use of this product is available for pregnant and lactating women. If this group of people need to use this vaccine, it is recommended to make a decision after the benefit-risk assessment together with a doctor.	Vaxigrip can be used in all stages of pregnancy. Vaxigrip may be used during breast-feeding.	Pregnant women should not receive Breastfeeding mother please consult your doctor.
Remarks	The above information is for reference only. If you have any question, please consult your doctor. For more detailed information, please visit website of Centre for Health Protection of DH: https://www.chp.gov.hk/en/features/100764.html 		

Version 20250919

¹ Serious chronic diseases are chronic diseases in which treatment has failed to treat the specific disease or the disease condition is beyond the clinical parameters that are considered safe or adequate by healthcare professionals.